Hyperphosphatemia: The hidden killer in chronic kidney disease

Saudi Medical Journal

Volumn 36, Issue 1, 2015, Pages 13-19

  Askar, Akram M ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ANTIOXIDANT; CALCIUM SALT; CHITOSAN; FETUIN A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRON SALT; LANTHANUM CARBONATE; NICOTINAMIDE; OSTEOCALCIN; PARATHYROID HORMONE; PHOSPHORUS; PYROPHOSPHATE; SEVELAMER; SIALOPROTEIN; SODIUM PHOSPHATE COTRANSPORTER;

APOPTOSIS; BLOOD VESSEL CALCIFICATION; CHRONIC KIDNEY DISEASE; DIET RESTRICTION; FOLLOW UP; GENE EXPRESSION; HEMODIALYSIS; HOSPITALIZATION; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; HYPERPHOSPHATEMIA; MORTALITY; NONHUMAN; OXIDATIVE STRESS; PHOSPHATE INTAKE; REVIEW; UREMIA; BLOOD; CARDIOVASCULAR DISEASES; CHRONIC KIDNEY FAILURE; COMPLICATION; RISK FACTOR; VASCULAR CALCIFICATION;

CARDIOVASCULAR DISEASES; HUMANS; HYPERPHOSPHATEMIA; PARATHYROID HORMONE; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; VASCULAR CALCIFICATION;

EID: 84922068726     PISSN: 03795284     EISSN: 16583175     Source Type: Journal    
DOI: 10.15537/smj.2015.1.9843     Document Type: Review

References (53)

1. Gilbert S, Weiner D, Gipson DS, Perazella MA, Tonelli M. National Kidney Foundation’s Primer on Kidney Diseases. 6th ed. Boston (MA): Elsevier; 2014
2. Kuro-o M. Klotho in health and disease. Curr Opin Nephrol Hypertens 2012; 21: 362-368
3. Dhingra R, Sullivan LM, Fox CS, Wang TJ, D’Agostino RB Sr, Gaziano JM, et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 2007; 167: 879-885
4. Foley RN, Collins AJ, Herzog CA, Ishani A, Kalra PA. Serum phosphorus levels associate with coronary atherosclerosis in young adults. J Am Soc Nephrol 2009; 20: 397-404
5. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005; 16: 520-528
6. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218
7. Calò LA, Savica V, Piccoli A, Fusaro M, D’Angelo A, Davis PA. Reduction of hyperphosphatemia is related with the reduction of C-reactive protein in dialysis patients. Study in sevelamer-resistant dialysis patients treated with chitosan chewing gum as salivary phosphate binder. Ren Fail 2011; 33: 11-14
8. Giachelli CM. Vascular calcification mechanisms. J Am Soc Nephrol 2004; 15: 2959-2964
9. National Institute of Diseases and Digestive and Kidney Disease. US Renal Data System 2012 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Am J Kidney Dis 2013; 61: 1-480
10. Shamseddin MK, Parfrey PS. Sudden cardiac death in chronic kidney disease: epidemiology and prevention. Nat Rev Nephrol 2011; 7: 145-154
11. Garimella PS, Hart PD, O’Hare A, DeLoach S, Herzog CA, Hirsch AT. Peripheral artery disease and CKD: a focus on peripheral artery disease as a critical component of CKD care. Am J Kidney Dis 2012; 60: 641-654
12. Yang H, Curinga G, Giachelli CM. Elevated extracellular calcium levels induce smooth muscle cell matrix mineralization in vitro. Kidney Int 2004; 66: 2293-2299
13. Glassock RJ, Pecoits-Filho R, Barberato SH. Left ventricular mass in chronic kidney disease and ESRD. Clin J Am Soc Nephrol 2009; 4 Suppl 1: S79-S91
14. Nakamura S, Ishibashi-Ueda H, Niizuma S, Yoshihara F, Horio T, Kawano Y. Coronary calcification in patients with chronic kidney disease and coronary artery disease. Clin J Am Soc Nephrol 2009; 4: 1892-1900
15. Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K, et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000; 87: 10-17
16. Shanahan CM. Vascular calcification. Curr Opin Nephrol Hypertens 2005; 14: 361-367
17. El-Abbadi M, Giachelli CM. Arteriosclerosis, calcium phosphate deposition and cardiovascular disease in uremia: current concepts at the bench. Curr Opin Nephrol Hypertens 2005; 14: 519-524
18. Shanahan CM, Crouthamel MH, Kapustin A, Giachelli CM. Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ Res 2011; 109: 697-711
19. Chen NX, Moe SM. Vascular calcification: Pathophysiology and risk factors. Curr Hypertens Rep 2012; 14: 228-237
20. Karohl C, Raggi P. Current Insights in Chronic Kidney Disease-Mineral and Bone Disorder. Medscape Education Nephrology 2013. available from:http://www.medscape.org/viewarticle/779579
21. Hermans MM, Brandenburg V, Ketteler M, Kooman JP, van der Sande FM, Boeschoten EW, et al. Association of serum fetuin-A levels with mortality in dialysis patients. Kidney Int 2007; 72: 202-207
22. Wang AY, Woo J, Lam CW, Wang M, Chan IH, Gao P, et al. Associations of serum fetuin-A with malnutrition, inflammation, atherosclerosis and valvular calcification syndrome and outcome in peritoneal dialysis patients. Nephrol Dial Transplant 2005; 20: 1676-1685
23. Stenvinkel P, Wang K, Qureshi AR, Axelsson J, Pecoits-Filho R, Gao P, et al. Low fetuin-A levels are associated with cardiovascular death: Impact of variations in the gene encoding fetuin. Kidney Int 2005; 67: 2383-2392
24. Honda H, Qureshi AR, Heimbürger O, Barany P, Wang K, Pecoits-Filho R, et al. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis 2006; 47: 139-148
25. Hermans MM, Brandenburg V, Ketteler M, Kooman JP, van der Sande FM, Gladziwa U, et al. Study on the relationship of serum fetuin-A concentration with aortic stiffness in patients on dialysis. Nephrol Dial Transplant 2006; 21: 1293-1299
26. Adeney KL, Siscovick DS, Ix JH, Seliger SL, Shlipak MG, Jenny NS, et al. Association of serum phosphate with vascular and valvular calcification in moderate CKD. J Am Soc Nephrol 2009; 20: 381-387
27. Giachelli CM. The emerging role of phosphate in vascular calcification. Kidney Int 2009; 75: 890-897
28. Zhao MM, Xu MJ, Cai Y, Zhao G, Guan Y, Kong W, et al. Mitochondrial reactive oxygen species promote p65 nuclear translocation mediating high-phosphate-induced vascular calcification in vitro and in vivo. Kidney Int 2011; 79: 1071-1079
29. Al-Aly Z. Phosphate, oxidative stress, and nuclear factor-κB activation in vascular calcification. Kidney Int 2011; 79: 1044-1047
30. Bushinsky DA. Contribution of intestine, bone, kidney, and dialysis to extracellular fluid calcium content. Clin J Am Soc Nephrol 2010; 5 Suppl 1: S12-S22
31. Karohl C, de Paiva Paschoal J, de Castro MC, Elias RM, Abensur H, Romão JE Jr, et al. Effects of bone remodelling on calcium mass transfer during haemodialysis. Nephrol Dial Transplant 2010; 25: 1244-1251
32. Block GA, Spiegel DM, Ehrlich J, Mehta R, Lindbergh J, Dreisbach A, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005; 68: 1815-1824
33. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218
34. Young EW, Albert JM, Satayathum S, Goodkin DA, Pisoni RL, Akiba T, et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005; 67: 1179-1187
35. Neves KR, Graciolli FG, dos Reis LM, Graciolli RG, Neves CL, Magalhães AO, et al. Vascular calcification: contribution of parathyroid hormone in renal failure. Kidney Int 2007; 71: 1262-1270
36. Katsumata K, Kusano K, Hirata M, Tsunemi K, Nagano N, Burke SK, et al. Sevelamer hydrochloride prevents ectopic calcification and renal osteodystrophy in chronic renal failure rats. Kidney Int 2003; 64: 441-450
37. Benini O, D’Alessandro C, Gianfaldoni D, Cupisti A. Extra-phosphate load from food additives in commonly eaten foods: a real and insidious danger for renal patients. J Ren Nutr 2011; 21: 303-308
38. Savica V, Calò LA, Monardo P, Santoro D, Mallamace A, Muraca U, et al. Salivary phosphorus and phosphate content of beverages: implications for the treatment of uremic hyperphosphatemia. J Ren Nutr 2009; 19: 69-72
39. Bellinghieri G, Santoro D, Savica V. Emerging drugs for hyperphosphatemia. Expert Opin Emerg Drugs 2007; 12: 355-365
40. Savica V, Bellinghieri G, Monardo P, Muraca U, Santoro D. An update on calcium metabolism alterations and cardiovascular risk in patients with chronic kidney disease: questions, myths and facts. J Nephrol 2013; 26: 456-464
41. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007; 71: 438-441
42. Suki WN; Dialysis Clinical Outcomes Revisited Investigators. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients: results of a randomized clinical trial. J Ren Nutr 2008; 18: 91-98
43. Savica V, Monardo P, Santoro D, Mallamace A, Bellinghieri G. Time-dependent effect of sevelamerHCl on the cardiovascular system. Nephrol Dial Transplant 2008; 23: 2102-2103
44. Hutchison AJ, Speake M, Al-Baaj F. Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: a 4-week, dose-finding, open-label study with lanthanum carbonate. Nephrol Dial Transplant 2004; 19: 1902-1906
45. Hutchison AJ, Laville M; SPD405-313 Lanthanum Study Group. Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden. Nephrol Dial Transplant 2008; 23: 3677-3684
46. Takahashi Y, Tanaka A, Nakamura T, Fukuwatari T, Shibata K, Shimada N, et al. Nicotinamide suppresses hyperphosphatemia in hemodialysis patients. Kidney Int 2004; 65: 1099-1104
47. Savica V, Calò L, Santoro D, Monardo P, Granata A, Bellinghieri G. Salivary phosphate secretion in chronic kidney disease. J Ren Nutr 2008; 18: 87-90
48. Savica V, Calò LA, Caldarera R, Cavaleri A, Granata A, Santoro D, et al. Phosphate salivary secretion in hemodialysis patients: implications for the treatment of hyperphosphatemia. Nephron Physiol 2007; 105: 52-55
49. Savica V, Calò LA, Monardo P, Davis PA, Granata A, Santoro D, et al. Salivary phosphate-binding chewing gum reduces hyperphosphatemia in dialysis patients. J Am Soc Nephrol 2009; 20: 639-644
50. Savica V, Calò LA, Santoro D, Monardo P, Santoro G, Muraca U, et al. Salivary glands: a new player in phosphorus metabolism. J Ren Nutr 2011; 21: 39-42
51. Iida A, Kemmochi Y, Kakimoto K, Tanimoto M, Mimura T, Shinozaki Y, et al. Ferric citrate hydrate, a new phosphate binder, prevents the complications of secondary hyperparathyroidism and vascular calcification. Am J Nephrol 2013; 37: 346-358
52. Dwyer JP, Sika M, Schulman G, Chang IJ, Anger M, Smith M, et al. Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial. Am J Kidney Dis 2013; 61: 759-766
53. Wüthrich RP, Chonchol M, Covic A, Gaillard S, Chong E, Tumlin JA. Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients. Clin J Am Soc Nephrol 2013; 8: 280-289.